Warning Letter Wednesday® Posts

A weekly exploration of FDA warning letters and enforcement trends


November 13, 2024
Takeaway -

Product reviews are marketing claims

November 6, 2024
Takeaway -

Following SOPs is essential to compliance

October 30, 2024
Takeaway -

Discussing ingredient benefits is "marketing"

October 23, 2024
Takeaway -

Don’t engage with risky reviews

October 16, 2024
Takeaway -

Playful ads can attract scrutiny

October 9, 2024
Takeaway -

Well intentioned marketing claims can turn products into high-risk regulatory categories

October 2, 2024
Takeaway -

Learn from other’s mistakes

September 25, 2024
Takeaway -

When will FDA go after “Nature’s Ozempic” claims

September 18, 2024
Takeaway -

Do not over-explain clinical research

September 11, 2024
Takeaway -

Blogs are “labeling”

September 4, 2024
Takeaway -

Disease claims trigger deeper FDA review

August 28, 2024
Takeaway -

Cosmetics are not "FDA-approved"